tivitis during July-September 2007. Reported treatment included home remedies and a nonprescription, locally available, cream containing a sulfa drug. Review of municipal hospital records during June 1-September 30, 2007, identifi ed no additional cases of conjunctivitis. After the last case-patient died, 17 other persons were identifi ed with purulent conjunctivitis: 4 at the municipal hospital and 13 during active case-fi nding in schools and the community. All were treated with oral amoxicillin and chloramphenicol optic solution, and 76 contacts were treated prophylactically with oral rifampin. No further suspected BPF cases were detected. Test results for acute arbovirus infection and PCR were negative for all patients (Table) .
This outbreak of highly fatal illness is clinically compatible with BPF. Compatible features included young age, antecedent purulent conjunctivitis, signs and symptoms (i.e., antecedent conjunctivitis, fever 39.5Cº-41.0Cº, abdominal pain, nausea, vomiting, petechiae or ecchymoses), and high case-fatality rate. Epstein-Barr infection has reportedly produced similar symptoms (4) but with an illness lasting >7 days in contrast to the <24 hours for our case-patients.
We did not detect H. aegyptius in peripheral blood by culture or in serum or CSF by PCR in the 2 surviving children and in contacts of casepatients. One reason could be the remoteness of the investigation site, which resulted in improper sample collection, storage, and processing in the fi eld before samples reached reference laboratories. Hemagglutination tests for arboviruses have low specifi city. Therefore, another known or novel pathogen could have caused these cases.
Timely treatment with antimicrobial drugs for patients with suspected disease, prophylaxis of contacts, and treatment of children with conjunctivitis resulted in no additional cases. Intensive surveillance for febrile illness preceded by conjunctivitis, immediate treatment, contact prophylaxis, and appropriate prompt laboratory testing are essential for continued control of BPF in this region.
Hepatitis C Virus in Blood Donors, Brazil
To the Editor: The Fundação de Hematologia e Hemoterapia do Amazonas is a public health service in Manaus, Brazil, that is responsible for serologic screening the serum of all blood donations in the region. In the state of Amazon, 9.0% of donated blood is discarded on the basis of serologic fi ndings; discarding because of hepatitis C virus (HCV) antibodies declined from 1.25% in 1995 to 0.32% in 2007. The aim of this study was to characterize the serologic and molecular profi le of HCV-antibodypositive blood donors from the Fundação de Hematologia e Hemoterapia do Amazonas.
For the study, 154 donors were selected from a routine database of voluntary blood donors who had donated from September 2005 through April 2007 (82,851 donations). Fresh plasma samples were sent to the laboratory in Manaus through the usual transportation systems for regular donations; i.e., samples from 27 cities are transported by air for ≈2 hours, and samples from 21 localities are transported by boat or road, all under refrigerated conditions. An in-house standardized nested-PCR was used to detect HCV RNA (1). Genotype assignment was based on type-specifi c motifs on the sequenced amplicons delimited by primers HC11/ HC18 from the 5′ untranslated region (2) . Viral load was determined by commercial assay (HCV Monitor, Roche Molecular Systems, Inc., Branchburg, NJ, USA).
An association was observed between HCV RNA and donor age; the same trend was seen in the fi rst-time blood donor group. Associations between HCV-RNA detection and gender (p = 0.875) and place of donation (p = 0.989) were not signifi cant. Using 18-25 years of age as the reference group, we found that odds ratios (ORs) for having HCV viremia were higher for those 45-55 years of age (OR 8.19, p<0.001) and 35-45 years of age (OR 3.49, p = 0.003).
We observed increasing rates of RNA detection according to the signalto-cutoff (S/CO) ratio. However, some donors had a weak S/CO ratio (between 1 and 2) with positive nested-PCR tests (Figure) . Although adopting an S/CO ratio as a criterion for referring for further testing by recombinant immunoblot assay (RIBA) has been advocated by some groups (3), our data show that this criterion may be misleading and would deny a confi rmatory diagnosis by giving false-negative results for many persons.
A total of 113 samples were analyzed by RIBA; among 48 RIBA-reactive samples, 9 (18.8%) were negative for HCV RNA in plasma. However, because PCR results may sometimes be negative for persons who are actually infected, a single negative PCR result should not be relied on as evidence that virus has cleared from plasma. Such patients must be observed for years before they may be declared cured (4).
Among 97 RIBA-positive or -indeterminate samples, viral load was detectable in only 33 samples: 27 (81.8%) RIBA-positive samples and 6 (18.2%) RIBA-indeterminate samples. Only HCV genotypes 1 (87.1%) and 3 (12.9%) were found. Geographic distribution shows genotypes 1 and 3 in Manaus and only genotype 1 in other Amazon cities. This genotype geographic distribution is similar to that found for many Brazilian cities and Eastern countries and may refl ect the route of HCV introduction into the Amazon; the virus was probably brought to the Amazon region by European immigrants and blood-derived medicines imported to Brazil. This hypothesis is corroborated by the fi nding of genotype 3 exclusively in Manaus, suggesting that this city is the point of arrival of HCV and that new strains were disseminated from Manaus to inner localities. Historical reconstruction of HCV in Amazon could be attempted by using these isolates as well as others from hepatitis patients in the region, including genotype 2 (5).
We found a higher-than-expected rate of 50% for indeterminate immunoblot results among samples that were HCV-RNA positive by nested PCR. The presence of HCV RNA in plasma samples from 70%-75% of blood donors with indeterminate immunoblot results has also been reported by other groups in Brazil (6,7); however, in contrast, other investigators have reported RNA prevalence in such samples to be ≈2.5% (1,8) . Indeterminate RIBA test results can indicate seroconversion or seroreversion or, occasionally, a chronic infection when RNA HCV is detected in plasma (9, 10) . To provide better understanding of the meaning of these indeterminate results, ongoing follow-up studies are examining the immune status of these persons.
Our data offer insights for counseling of donors who have repeatedly HCV-reactive results. We suggest that Amazon region blood banks screen by enzyme immunoassay and use molecular testing as the fi rst supplemental test and that immunoblot be applied to the remaining HCV-RNA nonreactive samples to distinguish between true and false anti-HCV carriers. This new algorithm would save considerable resources currently spent on immunoblot-indeterminate persons in addition to HCV-RNA reactive persons who do not require further testing for confi rmation. Moreover, according to current policy, those with false-positive results may be reinstated as donors if they have negative retesting results after 6 months. 
